These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 36819490)

  • 81. Effects and Mechanisms of Anlotinib and Dihydroartemisinin Combination Therapy in Ameliorating Malignant Biological Behavior of Gastric Cancer Cells.
    Luo Q; Zhang S; Zhang D; Feng R; Li N; Chen W; Chen X; Yang S
    Curr Pharm Biotechnol; 2021; 22(4):523-533. PubMed ID: 32576126
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Inhibition of programmed death ligand 1 (PD-L1) expression in breast cancer cells by sesamin.
    Kongtawelert P; Wudtiwai B; Shwe TH; Pothacharoen P; Phitak T
    Int Immunopharmacol; 2020 Sep; 86():106759. PubMed ID: 32663768
    [TBL] [Abstract][Full Text] [Related]  

  • 83. PD-L1 silencing inhibits triple-negative breast cancer development and upregulates T-cell-induced pro-inflammatory cytokines.
    Lotfinejad P; Kazemi T; Safaei S; Amini M; Roshani Asl E; Baghbani E; Sandoghchian Shotorbani S; Jadidi Niaragh F; Derakhshani A; Abdoli Shadbad M; Silvestris N; Baradaran B
    Biomed Pharmacother; 2021 Jun; 138():111436. PubMed ID: 33667790
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Programmed cell death ligand - 1 expression in triple negative breast carcinoma and its prognostic significance in Indian population.
    Gajaria PK; Gupta MR; Patil A; Desai SB; Shet TM
    Indian J Pathol Microbiol; 2021; 64(4):664-670. PubMed ID: 34673583
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Antagonistic Pharmacological Interaction between Sirtuin Inhibitor Cambinol and Paclitaxel in Triple-Negative Breast Cancer Cell Lines: An Isobolographic Analysis.
    Wawruszak A; Luszczki J; Okon E; Czerwonka A; Stepulak A
    Int J Mol Sci; 2022 Jun; 23(12):. PubMed ID: 35742901
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Different effects of 4β-hydroxywithanolide E and withaferin A, two withanolides from Solanaceae plants, on the Akt signaling pathway in human breast cancer cells.
    Wang HC; Hu HH; Chang FR; Tsai JY; Kuo CY; Wu YC; Wu CC
    Phytomedicine; 2019 Feb; 53():213-222. PubMed ID: 30668401
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Knockdown of NCAPG promotes the apoptosis and inhibits the invasion and migration of triple‑negative breast cancer MDA‑MB‑231 cells via regulation of EGFR/JAK/STAT3 signaling.
    Li J; Zheng J; Lin B; Sun H; Lu S; Wang D; Huo H
    Exp Ther Med; 2023 Mar; 25(3):119. PubMed ID: 36815969
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Delivery of miR-424-5p via Extracellular Vesicles Promotes the Apoptosis of MDA-MB-231 TNBC Cells in the Tumor Microenvironment.
    Zhou Y; Yamamoto Y; Takeshita F; Yamamoto T; Xiao Z; Ochiya T
    Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33467725
    [TBL] [Abstract][Full Text] [Related]  

  • 89. PD-1 Cellular Nanovesicles Carrying Gemcitabine to Inhibit the Proliferation of Triple Negative Breast Cancer Cell.
    Zha H; Xu Z; Xu X; Lu X; Shi P; Xiao Y; Tsai HI; Su D; Cheng F; Cheng X; Chen H
    Pharmaceutics; 2022 Jun; 14(6):. PubMed ID: 35745835
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Positive correlation between programmed death ligand-1 and p53 in triple-negative breast cancer.
    Zeng Y; Wang CL; Xian J; Ye Q; Qin X; Tan YW; Cao YD
    Onco Targets Ther; 2019; 12():7193-7201. PubMed ID: 31564903
    [TBL] [Abstract][Full Text] [Related]  

  • 91. The pan-PI3K inhibitor GDC-0941 activates canonical WNT signaling to confer resistance in TNBC cells: resistance reversal with WNT inhibitor.
    Tzeng HE; Yang L; Chen K; Wang Y; Liu YR; Pan SL; Gaur S; Hu S; Yen Y
    Oncotarget; 2015 May; 6(13):11061-73. PubMed ID: 25857298
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Immunotherapy Targeting PD-1/PD-L1 in Early-Stage Triple-Negative Breast Cancer.
    Yang T; Li W; Huang T; Zhou J
    J Pers Med; 2023 Mar; 13(3):. PubMed ID: 36983708
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Breast Cancer Cells and PD-1/PD-L1 Blockade Upregulate the Expression of PD-1, CTLA-4, TIM-3 and LAG-3 Immune Checkpoints in CD4
    Saleh R; Toor SM; Khalaf S; Elkord E
    Vaccines (Basel); 2019 Oct; 7(4):. PubMed ID: 31614877
    [No Abstract]   [Full Text] [Related]  

  • 94. Beyond Anti-PD-1/PD-L1: Improving Immune Checkpoint Inhibitor Responses in Triple-Negative Breast Cancer.
    Bullock KK; Richmond A
    Cancers (Basel); 2024 Jun; 16(12):. PubMed ID: 38927895
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Blockade of CCL2 expression overcomes intrinsic PD-1/PD-L1 inhibitor-resistance in transglutaminase 2-induced PD-L1 positive triple negative breast cancer.
    Choi J; Lee HJ; Yoon S; Ryu HM; Lee E; Jo Y; Seo S; Kim D; Lee CH; Kim W; Ha JY; Kim SY; Gong G; Jung KH; Park SR; Kim SW; Park KS; Lee DH
    Am J Cancer Res; 2020; 10(9):2878-2894. PubMed ID: 33042623
    [TBL] [Abstract][Full Text] [Related]  

  • 96. The therapeutic candidate for immune checkpoint inhibitors elucidated by the status of tumor-infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) expression in triple negative breast cancer (TNBC).
    Tomioka N; Azuma M; Ikarashi M; Yamamoto M; Sato M; Watanabe KI; Yamashiro K; Takahashi M
    Breast Cancer; 2018 Jan; 25(1):34-42. PubMed ID: 28488168
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Cannabidiol enhances Atezolizumab efficacy by upregulating PD-L1 expression via the cGAS-STING pathway in triple-negative breast cancer cells.
    Kim BG; Kim BR; Kim DY; Kim WY; Kang S; Lee SI; Oh SC
    Cancer Immunol Res; 2024 Sep; ():. PubMed ID: 39226389
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Programmed death ligand-1 regulates angiogenesis and metastasis by participating in the c-JUN/VEGFR2 signaling axis in ovarian cancer.
    Yang Y; Xia L; Wu Y; Zhou H; Chen X; Li H; Xu M; Qi Z; Wang Z; Sun H; Cheng X
    Cancer Commun (Lond); 2021 Jun; 41(6):511-527. PubMed ID: 33939321
    [TBL] [Abstract][Full Text] [Related]  

  • 99. INPP4B overexpression enhances the antitumor efficacy of PARP inhibitor AG014699 in MDA-MB-231 triple-negative breast cancer cells.
    Sun Y; Ding H; Liu X; Li X; Li L
    Tumour Biol; 2014 May; 35(5):4469-77. PubMed ID: 24420152
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Efficacy and safety profiles of programmed cell death-1/programmed cell death ligand-1 inhibitors in the treatment of triple-negative breast cancer: A comprehensive systematic review.
    Lazarus G; Audrey J; Iskandar AWB
    Oncol Rev; 2019 Jul; 13(2):425. PubMed ID: 31857857
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.